Stocktoria
Eloxx Pharmaceuticals, Inc. ELOX
Eloxx Pharmaceuticals, Inc. financials (annual)
Bars are annual figures from 2017 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $6.4M | $0 | — | — | — | — | — | — | — |
| R&D expense | — | — | — | — | — | $14.6M | $26.3M | $20.5M | $16.4M | $280,240 |
| Operating income | -$6.4M | -$2.5M | -$17.3M | -$34.4M | -$66.0M | -$33.5M | -$50.6M | -$47.6M | -$20.4M | -$2.2M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $122,000 | — | -$640,000 |
| Net income | -$6.0M | -$3.1M | -$17.1M | -$36.1M | -$66.7M | -$34.6M | -$50.9M | -$47.2M | -$21.2M | -$933,577 |
| EPS (diluted) | $-0.49 | $-0.84 | $-6.63 | $-16.65 | $-38.15 | — | — | — | — | — |
| Operating cash flow | -$6.3M | -$4.7M | -$14.3M | -$31.8M | -$35.0M | -$28.2M | -$39.4M | -$31.4M | -$15.9M | -$1.9M |
| Free cash flow | — | — | — | -$31.9M | -$35.1M | — | -$39.4M | -$31.6M | -$16.2M | -$1.9M |
| Cash & equivalents | $4.8M | $111,000 | $1.1M | $19.2M | $42.3M | $24.7M | $22.5M | $48.6M | $24.0M | $13.4M |
| Total assets | $5.3M | $3.0M | $1.7M | $21.1M | $45.1M | $26.5M | $58.9M | $50.7M | $24.8M | $5.8M |
| Total liabilities | $17.2M | $27.3M | $24.3M | $31.8M | $22.8M | $16.2M | $22.7M | $7.8M | — | $5.0M |
| Shareholders' equity | -$11.9M | -$24.3M | -$22.6M | -$10.7M | $22.4M | $10.2M | $36.2M | $42.9M | $21.4M | $871,206 |
Growth · year-over-year
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | -100.0% | — | — | — | — | — | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.